[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.171.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
May 27, 2002

Selective COX-2 Inhibitors, NSAIDs, Aspirin, and Myocardial Infarction

Author Affiliations
 

Not Available

Arch Intern Med. 2002;162(10):1091-1092. doi:10.1001/archinte.162.10.1091

NONSTEROIDAL ANTI-INFLAMMATORY drugs (NSAIDs) are among the most widely used medications in the world.1 NSAIDs inhibit cyclooxygenase-1 (COX-1) and COX-2 isoenzymes. Inhibition of COX-1 isoenzymes inhibits the production of thromboxane and thus inhibits platelet aggregation. In addition, inhibition of COX-1 isoenzymes compromises the gastrointestinal mucosa. As a result, the major limitation of NSAIDs is gastrointestinal toxicity, resulting in upper gastrointestinal events in 2% to 4% of patients per year.1

First Page Preview View Large
First page PDF preview
First page PDF preview
×